Patents by Inventor Vijay Naringrekar

Vijay Naringrekar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sustained release GLP-1 receptor modulators
    Publication number: 20070099835
    Abstract: The present invention provides novel pharmaceutical compositions comprising a human glucagon-like peptide-1 (GLP-1)-receptor modulator as an active ingredient in a sustained release formulation.
    Type: Application
    Filed: November 8, 2006
    Publication date: May 3, 2007
    Inventors: Feng Qian, William Ewing, Claudio Mapelli, Douglas Riexinger, Ving Lee, Richard Sulsky, Yeheng Zhu, Tasir Haque, Rogelio Martinez, Vijay Naringrekar, Nina Ni, Lori Burton
  • Aripiprazole complex formulation and method
    Publication number: 20060234979
    Abstract: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a ?-cyclodextrin, preferably, sulfobutyl ether ?-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Application
    Filed: June 14, 2006
    Publication date: October 19, 2006
    Inventors: Manoj Nerurkar, Vijay Naringrekar
  • Aripiprazole complex formulation and method
    Patent number: 7115587
    Abstract: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a ?-cyclodextrin, preferably, sulfobutyl ether ?-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Grant
    Filed: August 14, 2003
    Date of Patent: October 3, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Manoj Nerurkar, Vijay Naringrekar
  • Process and formulation containing epothilones and analogs thereof
    Publication number: 20050171167
    Abstract: A process for formulating certain epothilones and analogs thereof for parenteral administration is provided wherein the pH of the formulation for administration can be controlled to enhance the stability and thus, potency of the epothilone, or analog thereof.
    Type: Application
    Filed: November 3, 2004
    Publication date: August 4, 2005
    Inventors: Thomas Haby, Uday Gogate, Vijay Naringrekar
  • Controlled release sterile injectable aripiprazole formulation and method
    Publication number: 20050148597
    Abstract: A controlled release sterile freeze-dried aripiprazole formulation is provided which is formed of aripiprazole of a desired mean particle size and a vehicle therefor, which upon constitution with water and intramuscular injection releases aripiprazole over a period of at least about one week and up to about eight weeks. A method for preparing the controlled release freeze-dried aripiprazole formulation, and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Application
    Filed: October 19, 2004
    Publication date: July 7, 2005
    Inventors: Janusz Kostanski, Takakuni Matsuda, Manoj Nerurkar, Vijay Naringrekar
  • Aripiprazole complex formulation and method
    Publication number: 20040077594
    Abstract: An aripiprazole formulation is provided which includes the antipsychotic agent aripiprazole in the form of an inclusion complex in a &bgr;-cyclodextrin, preferably, sulfobutyl ether &bgr;-cyclodextrin (SBECD), which in the form of an injectable produces reversible generally minimal to mild irritation at the intramuscular injection site. A method for minimizing or reducing irritation caused by aripiprazole at an intramuscular injection site and a method for treating schizophrenia employing the above formulation are also provided.
    Type: Application
    Filed: August 14, 2003
    Publication date: April 22, 2004
    Inventors: Manoj Nerurkar, Vijay Naringrekar, Mark Dominick